MYD88 and type 1 diabetes mellitus: Unlike the findings observed in the T1DM mouse model, EcN-GLP-1 exhibited the capability to mitigate pancreatic inflammation by reducing the expressions of MyD88, while the effects on TLR-4 and p-NF-κB/NF-κB were not obvious.